Upstream Bio, Inc. presented data on June 15, 2025, at the European Academy of Allergy & Clinical Immunology Congress in Glasgow, indicating that its treatment verekitug shows greater potency than tezepelumab for targeting inflammatory diseases. This monoclonal antibody, which inhibits the TSLP receptor, is currently undergoing Phase 2 clinical trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with plans to initiate trials for chronic obstructive pulmonary disease (COPD).
The pharmacology modeling data demonstrated that verekitug achieves complete and sustained inhibition of the TSLP/TSLPR complex, leading to significant reductions in lung inflammation, as indicated by fractional exhaled nitric oxide (FeNO) levels. Upcoming trial results for CRSwNP are expected in Q3 2025, followed by data for severe asthma in H1 2026, highlighting verekitug’s potential to meet unmet medical needs in severe respiratory conditions.
